Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea--(BUSINESS WIRE)--Oct 23, 2023--
Source: eagletribune.com
📰 Sie Djohan News
Sie Djohan News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sie Djohan. Real-time updates on events, politics, business and more.
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with PT Kalbe Genexine Biologics ("KGbio"), an...
Source: prnewswire.com
General Atlantic to invest $55 million in Indonesia's Kalbe Farma biotech JV | WSAU News/Talk 550 AM · 99.9 FM
General Atlantic to invest $55 million in Indonesiaâs Kalbe Farma biotech JV By Syndicated Content Jan 26, 2021 11:10 PM SINGAPORE (Reuters) - Global private equity firm General Atlantic will invest $55 million in Kalbe Genexine Biologics (KGBio), a joint venture of Indonesian pharmaceuticals firm PT Kalbe Farma and South Korean biotech firm Genexine Inc. The investment will go towards KGBios ongoing clinical development and help boost its production capacity, among others, the...
Source: wsau.com
PT Kalbe Farma Tbk (via Public) / Kalbe Gets Phase-2 Clinical Trial Approval on COVID-19 Drug
Kalbe Gets Phase-2 Clinical Trial Approval on COVID-19 Drug - GX17 Kalbe Gets Phase-2 Clinical Trial Approval on COVID-19 Drug - GX17 Jakarta, 30 December 2020 - PT Kalbe Farma Tbk (Kalbe) through its subsidiary PT Kalbe-Genexine Biologics (KGBio) today has received approval for a clinical trial (PPUK) from the Food and Drug Administration of the Republic of Indonesia (BPOM) to carry out Phase 2 clinical trials of the drug GX-17, which is an immunotherapeutic drug that will be developed as a tr...
South Korea Jakarta Raya Republic Of Indonesia Kalbe Genexine Biologics Asia Pacific Kalbe Genexine Biologics Kgbio
Source: publicnow.com